November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index climb a whopping 18%. This outpaced the S&P and Nasdaq as smaller companies are really...
On Monday morning, Pfizer (PFE) announced that they have a very effective vaccine for Covid-19. This, combined with what appears to be a clear result in the presidential election, sparked a very strong rally in the stock market. Normally a...
What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity to send a message to thousands of readers. It's a privilege that I don't take...
Small and micro-cap stocks have underperformed the market for quite a while now. Since I started Tailwinds in August of 2016, the Russell 2000 has underperformed the S&P 500 every year. The cumulative effect is a total return of...
Having survived the rocky cliffs of Moab, I think I jinxed myself with last week's cover photo asking "What could go wrong?" Turns out we learned the answer on Monday as just about everything in our universe got taken...
Tailwinds' Take: DYAI has a number of balls in the air when it comes to Covid-19. We continue to believe that the pandemic is accelerating their programs towards entering human trials. We think the next year will see major...
Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand at the end of Q3 with the S&P having climbed 8.5% in the quarter and...
Markets were very volatile this past week, trading back and forth like a game of ping-pong. There's little doubt in my mind that the pickup in volatility of the last few weeks will remain here through the election, if...
Tailwinds' Take: Dyadic's disruptive technology is being explored for use in vaccine production by many partners. There's an excellent chance they will be successfully used for a Covid-19 vaccine and that would be game changing for the stock. During the...
After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have, very thankfully, missed the smoke and clear skies await. Now, if we can survive the...
Tailwinds' Take: Jiangsu is one of the two largest pharmaceutical companies in China. "This is a major shot across the bow of big pharma," according to CEO Mark Emalfarb. We expect C1 to eventually become a very large component...
Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell getting closer to positive territory for the year. Meanwhile, in a move that has many...
Tailwinds Take: Dyadic continues to execute on their business but the street will likely focus on the ATM and pressure the shares. When we see a first-in-human drug candidate, the rhetoric around DYAI will change permanently for the positive....
Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth permanently, consistent with the Executive Order on Improving Rural and Telehealth Access that President Trump...
There's certainly a lot going on in the world at large right now and none of it seems too good. Covid-19 refuses to go away, a cold war is developing with China and our government can't decide on another...
Tailwinds' Take: as we said recently, the onset of Covid-19 is driving recognition and rapid adoption of DYAI's C1 technology. The pipeline is bursting and we should start seeing human testing on C1 engineered products this fall with a...
Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding and, in a complete shocker to those from the Bay Area, Mrs. Carlson can get...
Tailwinds' Take: the momentum in Dyadic's business is growing. They are on the verge of changing the production of a large chunk of the biologics industry. These fully funded collaborations are simply more confirmation of where things are headed...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.